New study aims to personalize septic shock treatment with biomarkers

NCT ID NCT05824767

Completed Knowledge-focused Sponsor: University of New Mexico Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This completed pilot study tested whether two biomarkers (renin and DPP3) can predict how well patients with septic shock respond to angiotensin II, a drug that raises blood pressure. Forty adults with persistent low blood pressure despite standard treatment were randomly assigned to receive either angiotensin II or usual care. The main goal was to see if baseline biomarker levels could predict the amount of other blood pressure medications needed after 3 hours.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Angiotensin II (Giapreza)
What this could lead to: If successful, this could help doctors predict which septic shock patients will respond best to angiotensin II, potentially improving treatment decisions.
What could go wrong: This is a small, early pilot study with only 40 patients, so results may not apply broadly. The study is unblinded, which can introduce bias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEPTIC SHOCK VASODILATORY SHOCK

Contacts and locations

Locations

University of New Mexico Health Sciences Center

Albuquerque, New Mexico, 87106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.